Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures
Disease overview Chronic lymphocytic leukemia (CLL) is one of the most frequent types of
leukemia. It typically occurs in elderly patients and has a highly variable clinical course …
leukemia. It typically occurs in elderly patients and has a highly variable clinical course …
Role of Bruton's tyrosine kinase in B cells and malignancies
Bruton's tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic
signaling that is critical for proliferation and survival of leukemic cells in many B cell …
signaling that is critical for proliferation and survival of leukemic cells in many B cell …
Venetoclax–rituximab in relapsed or refractory chronic lymphocytic leukemia
Background Venetoclax inhibits BCL2, an antiapoptotic protein that is pathologically
overexpressed and that is central to the survival of chronic lymphocytic leukemia cells. We …
overexpressed and that is central to the survival of chronic lymphocytic leukemia cells. We …
Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience
G Salles, M Barrett, R Foà, J Maurer, S O'Brien… - Advances in …, 2017 - Springer
Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established
efficacy, and a favorable and well-defined safety profile in patients with various CD20 …
efficacy, and a favorable and well-defined safety profile in patients with various CD20 …
BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies
A Alu, H Lei, X Han, Y Wei, X Wei - Journal of Hematology & Oncology, 2022 - Springer
Bruton's tyrosine kinase (BTK) is an essential component of multiple signaling pathways that
regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising …
regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising …
Inhibitors targeting Bruton's tyrosine kinase in cancers: drug development advances
T Wen, J Wang, Y Shi, H Qian, P Liu - Leukemia, 2021 - nature.com
Bruton's tyrosine kinase (BTK) inhibitor is a promising novel agent that has potential
efficiency in B-cell malignancies. It took approximately 20 years from target discovery to new …
efficiency in B-cell malignancies. It took approximately 20 years from target discovery to new …
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic …
B Eichhorst, AM Fink, J Bahlo, R Busch… - The lancet …, 2016 - thelancet.com
Background Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab is
the standard therapy for physically fit patients with advanced chronic lymphocytic leukaemia …
the standard therapy for physically fit patients with advanced chronic lymphocytic leukaemia …
[HTML][HTML] Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
Clinical trials that led to ibrutinib's approval for the treatment of chronic lymphocytic leukemia
showed that its side effects differ from those of traditional chemotherapy. Reasons for …
showed that its side effects differ from those of traditional chemotherapy. Reasons for …
Targeting B cell receptor signalling in cancer: preclinical and clinical advances
JA Burger, A Wiestner - Nature Reviews Cancer, 2018 - nature.com
B cell receptor (BCR) signalling is crucial for normal B cell development and adaptive
immunity. BCR signalling also supports the survival and growth of malignant B cells in …
immunity. BCR signalling also supports the survival and growth of malignant B cells in …
Chronic lymphocytic leukaemia
Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in
the past two decades have led to the development of new prognostic tools and novel …
the past two decades have led to the development of new prognostic tools and novel …